Dataset Information

An evidence-based review of the potential role of icatibant in the treatment of acute attacks in hereditary angioedema type I and II.

ABSTRACT:

Introduction

Icatibant, a first-in-class B2 bradykinin receptor antagonist, appears to have a favorable efficacy and safety profile for the treatment of acute attacks of hereditary angioedema in adults.

Aims

To update the evidence and provide an overview of the available data on icatibant.

Evidence review

Peer reviewed articles published and listed in Medline Search and published updated guidelines for the treatment of acute attacks in hereditary angioedema type I and II in adults were reviewed. The validity and quality of evidence were evaluated.

Place in therapy

Clinical evidence for the treatment of acute hereditary angioedema attacks with icatibant is strong. Approximately 10% of the patients require a second dose. No serious adverse reactions have been reported. The only significant side effects consistently registered by 90% of patients are transient local pain, swelling, and erythema at the local injection site.

Conclusion

Subcutaneously administered 30 mg icatibant has been shown to be a safe and efficacious treatment in clinical trials. It is the only specific treatment authorized for self-administration by the subcutaneous route offering increased patient independence.

SUBMITTER: Floccard B

PROVIDER: S-EPMC3467996 | biostudies-literature | 2012

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

An evidence-based review of the potential role of icatibant in the treatment of acute attacks in hereditary angioedema type I and II.

Floccard Bernard B Hautin Etienne E Bouillet Laurence L Coppere Brigitte B Allaouchiche Bernard B

Core evidence 20120927

<h4>Introduction</h4>Icatibant, a first-in-class B2 bradykinin receptor antagonist, appears to have a favorable efficacy and safety profile for the treatment of acute attacks of hereditary angioedema in adults.<h4>Aims</h4>To update the evidence and provide an overview of the available data on icatibant.<h4>Evidence review</h4>Peer reviewed articles published and listed in Medline Search and published updated guidelines for the treatment of acute attacks in hereditary angioedema type I and II in ...[more]

PMID: 23055948

Similar Datasets

Project description:Hereditary angioedema (HAE) is an autosomal dominant, potentially life-threatening condition, manifesting as recurrent and self-limiting episodes of facial, laryngeal, genital, or peripheral swelling with abdominal pain secondary to intra-abdominal edema. The estimated prevalence of HAE in the general population is one individual per 50,000, with reported ranges from 1:10,000 to 1:150,000, without major sex or ethnic differences. Various treatment options for acute attacks and prophylaxis of HAE are authorized and available in the market, including plasma-derived (Berinert®, Cinryze®, and Cetor®) and recombinant (Rhucin® and Ruconest™) C1 inhibitors, kallikrein inhibitor-ecallantide (Kalbitor®), and bradykinin B2 receptor antagonist-icatibant (Firazyr®). Some of these drugs are used only to treat HAE attacks, whereas others are only approved for prophylactic therapies and all of them have improved disease outcomes due to their different mechanisms of action. Bradykinin and its binding to B2 receptor have been demonstrated to be responsible for most of the symptoms of HAE. Thus icatibant (Firazyr®), a bradykinin B2 receptor antagonist, has proven to be an effective and more targeted treatment option and has been approved for the treatment of acute attacks of HAE. Rapid and stable relief from symptoms of cutaneous, abdominal, or laryngeal HAE attacks has been demonstrated by 30 mg of icatibant in Phase III clinical trials. Self-resolving mild to moderate local site reactions after subcutaneous injection of icatibant were observed. Icatibant is a new, safe, and effective treatment for acute attacks of HAE. HAE has been reported to result in enormous humanistic burden to patients, affecting both physical and mental health, with a negative impact on education, career, and work productivity, and with substantial economic burdens. The timely and proper use of disease-specific treatments could improve patients' quality of life, reduce the disease-specific morbidity and mortality, and, last but not least, reduce costs associated with hospitalizations and emergency room visits. Therefore, the paradigm of HAE treatment has the potential to evolve significantly, thereby exponentially improving a patient's quality of life.

Dataset Information

An evidence-based review of the potential role of icatibant in the treatment of acute attacks in hereditary angioedema type I and II.

Introduction

Aims

Evidence review

Place in therapy

Conclusion

Publications

An evidence-based review of the potential role of icatibant in the treatment of acute attacks in hereditary angioedema type I and II.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets